Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
复制标题
DOI：
10.1007/s00213-017-4771-x
复制
发表时间：
2018-03
影响因子：
3.4
通讯作者：
Nutt DJ
中科院分区：
文献类型：
--
作者：
Carhart-Harris RL;Bolstridge M;Day CMJ;Rucker J;Watts R;Erritzoe DE;Kaelen M;Giribaldi B;Bloomfield M;Pilling S;Rickard JA;Forbes B;Feilding A;Taylor D;Curran HV;Nutt DJ
最近的临床试验报告了迷幻药物辅助心理治疗对心理健康结果的显著改善。在这里，我们报告了裸盖菇素治疗难治性抑郁症长达6个月的安全性和有效性结果。20例（大多数）严重、单极、难治性重度抑郁症患者（6名女性）在支持环境下口服两剂裸盖菇素（10和25毫克，间隔7天）。治疗后1周至6个月对抑郁症状进行评估，以自评QIDS-SR16作为主要结局指标。治疗总体耐受良好。相对于基线，在治疗后的前5周观察到抑郁症状的显著减轻（第1周Cohen’s d = 2.2，第5周为2.3，p均< 0.001）；9例和4例患者在第5周达到缓解和缓解标准。结果在3个月和6个月时保持阳性（Cohen’s d分别= 1.5和1.4，p均< 0.001）。在使用裸盖菇素的5周内，没有患者寻求常规抗抑郁治疗。急性迷幻体验的质量可以预测5周后抑郁症状的减轻。尽管从开放标签试验中得出的治疗效果结论有限，但耐受性良好，效应量大，仅在两次裸盖菇素治疗后症状改善迅速出现，并且在治疗后6个月仍显着。裸盖菇素代表了一种有希望的治疗无反应性抑郁症的范例，值得在双盲随机对照试验中进一步研究。本文的在线版本（10.1007/s00213-017-4771-x）包含补充材料，仅供授权用户使用。
Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure. Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen’s d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen’s d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials. The online version of this article (10.1007/s00213-017-4771-x) contains supplementary material, which is available to authorized users.
登录
查看更多内容
DOI：
10.1177/0269881108093587
发表时间：
2008-08
期刊：
Journal of psychopharmacology (Oxford, England)
影响因子：
--
作者：
Johnson M;Richards W;Griffiths R
通讯作者：
Griffiths R
影响因子：
5.3
作者：
Moreno, Francisco A.;Wiegand, Christopher B.;Delgado, Pedro L.
通讯作者：
Delgado, Pedro L.
影响因子：
--
作者：
Osório, Flávia de L.;Sanches, Rafael F.;Hallak, Jaime E.
通讯作者：
Hallak, Jaime E.
DOI：
10.1177/0269881116675513
发表时间：
2016-12
期刊：
Journal of psychopharmacology (Oxford, England)
影响因子：
--
作者：
Griffiths RR;Johnson MW;Carducci MA;Umbricht A;Richards WA;Richards BD;Cosimano MP;Klinedinst MA
通讯作者：
Klinedinst MA
影响因子：
3.7
作者：
Branchi, Igor
通讯作者：
Branchi, Igor